Latest by Myles Helfand

It's World AIDS Day. Who Cares? A Blog Entry by Myles Helfand

"To most of humanity, today is World AIDS Day. To most of the world's 33 million people who are living with HIV, it's Wednesday," writes's editorial director Myles Helfand. "Tomorrow, Dec. 2, the world will move on to its next topic, sati...

By Myles Helfand

A Closer Look at Egrifta, a Newly Approved Treatment for HIV-Associated Belly Fat Gain (Lipohypertrophy)

Egrifta (tesamorelin) is the first drug approved in the U.S. to treat unusual fat gain, or lipohypertrophy, in people with HIV. In our latest episode of This Month in HIV, we talk with noted HIV researcher Daniel Berger, M.D., about how Egrifta wor...

By Myles Helfand

Selzentry Labeling Includes New Warnings for People With Kidney Problems: A Blog Entry by Myles Helfand

The CCR5 inhibitor Selzentry (Celsentri, maraviroc) should be used with caution by HIV-positive people with kidney problems, according to a U.S. Food and Drug Administration release. The release provides details on several changes that have just been...

By Myles Helfand

Restarting the Conversation on HIV/AIDS in the United States

There's an HIV/AIDS epidemic raging in the U.S., though we can perhaps forgive people for having no clue that it exists. After all, you can't learn about it by picking up a newspaper or flipping on the television; it's not the kind of topic mainstrea...

By Myles Helfand

HIV/AIDS Clinic in Port-au-Prince, Haiti, Hit Hard by Earthquake; How You Can Help: A Blog Entry by Myles Helfand

A quick note on some HIV/AIDS-related news trickling out of Haiti in the aftermath of this week's devastating earthquake: A key HIV/AIDS clinic in Haiti, the GHESKIO facility in Port-au-Prince, has been severely damaged but most of its staff is accou...

By Myles Helfand

The Thai HIV Vaccine Trial: Is It a Big Deal or Not? A Blog Entry by Myles Helfand

If you're feeling a sense of whiplash over the recent barrage of HIV/AIDS vaccine news, you're not alone: Public reaction to the initial results of the RV144 Thai HIV vaccine trial felt like a roller coaster.

First came the over-the-top headlines ha...

By Myles Helfand

ADAP Coverage Struggling in Many States, Leaving Many HIVers in the Lurch: A Blog Entry by Myles Helfand

HIV vaccine in Thailand = sexy. HIV treatment access in U.S. = yawn.

That's the lesson we can apparently take away from the news of the past two weeks. On the one hand, you have The Big News of the Year: Heralds throughout the U.S. trumpeted the sto...

By Myles Helfand

25-Year Prison Sentence Vanishes for Man Convicted of Not Disclosing HIV Status: A Blog Entry by Myles Helfand

Twenty-five years in prison and a lifetime of parole. That's the sentence that was initially handed down to Nick Rhoades, a 34-year-old, HIV-positive man living in Iowa. His crime: Failing to disclose his HIV status to another man before having sex w...

By Myles Helfand

How Long Will You Live With HIV? Take Studies With a Grain of Salt: A Blog Entry by Myles Helfand

"How long will I live?"

It's one of the most pressing, frightening questions facing people with HIV, whether they've been newly diagnosed or have been infected for some time. And like so many other questions in HIV, the answer is frustratingly compl...

By Myles Helfand

Kaletra and Gemfibrozil (Lopid): A Match Not Made in Lipid Heaven: A Blog Entry by Myles Helfand

Here's a heads-up for those of you with HIV and high cholesterol/triglycerides: Depending on which HIV meds you're taking, lipid-busting drugs may not work exactly the way they're supposed to.

The latest item to add to your "Oh Great, Another Thing ...

By Myles Helfand